57th ASH Annual Meeting and Exposition (December 5-8, 2015): 332. Antithrombotic Therapy II

Antithrombotic Therapy Oral and Poster Abstracts
Oral

W307, Level 3 (Orange County Convention Center)

Moderators:

Anita Rajasekhar, MD, MS, University of Florida and Mary Cushman, University of Vermont

Disclosures:

Cushman: Daiichi Sankyo: Other: single advisory board meeting .

6:15 PM

Individually Tailored Prophylaxis Using a Risk Score for the Management of Pregnant Women with Increased Risk of Venous Thromboembolism

Yesim G. Dargaud, MD, PhD¹, Lucia Rugeri²^*, Chloe Fleury²^*, Helene Desmurs Clavel²^*, Jacques Ninet²^*, Catherine Battie³^*, Pascal Gaucherand³^*, Cyril Huissoud⁴^*, Rene Charles Rudigoz⁴^* and Christine Trzeciak²^*

¹Hopital Edouard Herriot Pav. E, Lyon, France
²Hopital Edouard Herriot, Lyon, France
³Centre Hospitalier Lyon Est, Lyon, France
⁴Centre Hospitalier Lyon Nord, Lyon, France

6:30 PM

890

Low Molecular Weight Heparin for Prevention of Placenta-Mediated Pregnancy Complications: An Individual Patient Data Meta-Analysis

Marc Rodger, MD, MSc¹, Johanna IP de Vries, MD PhD²^*, Evelyne Rey, MD³^*, Jean-Christophe JCG Gris, MD PhD⁴^*, Ida Martinelli, MD⁵^*, Ekkehard Schleussner, MD⁶^*, Saskia Middeldorp, MD, PhD⁷, Shannon M Bates, MD, MSc⁸, Paulien de Jong, MD PhD⁹^*, Nicole Langlois¹⁰^*, Ranjeeta Mallick¹¹^*, Ranjeeta Mallick¹¹^*, Timothy Ramsay¹¹^*, David Petroff¹²^*, Dick Bezemer¹³^*, Marion van Hoorn²^*, Carolien Abheiden²^*, Risto Kaaja, MD, PhD¹⁴^*, Annalisa Perna¹⁵^* and Alain Mayhew¹¹^*

¹Ottawa Blood Disease Center, University of Ottawa and Ottawa Hospital Research Institute, Ottawa, ON, Canada
²Department of Obstetrics and Gynecology, VU University Medical Center, Amsterdam, Netherlands
³CHU Ste-Justine, Montreal, Canada
⁴CHU Nimes, Nimes, France
⁵A. Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy
⁶Department of Obstetrics and Gynecology, Jena University Hospital, Jena, Germany
⁷Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
⁸Department of Medicine, McMaster University, Hamilton, ON, Canada
⁹Amsterdam Medical Center, Amsterdam, Netherlands
¹⁰Ottawa Blood Disease Center, Ottawa Health Research Institute, Ottawa, Canada
¹¹Ottawa Health Research Institute, Ottawa, Canada
¹²University of Leipzig, Leipzig, Germany
¹³VU University Medical Center, Amsterdam, Netherlands
¹⁴Helsinki Univ. Hosp., Turku Univ., Pori, Finland
¹⁵Centro di Richerche Cliniche per le Malattie Rare, Ranica, Italy

6:45 PM

891

The Bleeding Risk of Vitamin K Antagonists Hardly Increases after the Age of 80 Years: Data from a Large Real-Life Cohort Study

Hilde Kooistra, MD^1,2^*, Agneta Calf, MD³^*, Margriet Piersma-Wichers, MD^1,2^*, Gerbrand Izaks, MD⁴^*, Nic Veeger, MSc⁵^* and Karina Meijer, MD, PhD⁶

¹Certe Thrombosis Service Groningen, Groningen, Netherlands
²Division of Hemostasis and Thrombosis, Department of Hematology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
³Department of Internal Medicine, Medical Center Leeuwarden, Leeuwarden, Netherlands
⁴University Center for Geriatric Medicine, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
⁵Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
⁶Division of Hemostasis and Thrombosis, Department of Hematology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands

7:00 PM

892

Pattern and Management of ISTH Major Bleeding Complications with Direct Oral Anticoagulants - Results of the Prospective Dresden Noac Registry (NCT01588119)

Sandra Marten, MD^*, Luise Tittl, B.Sc.^*, Katharina Daschkow^* and Jan Beyer-Westendorf, MD

Vascular Medicine, Dresden University Hospital, Dresden, Germany

7:15 PM

893

A Prospective Cohort Study of Upper Extremity Deep Vein Thrombosis

Alejandro Lazo-Langner, MD, MSc¹, Susan R Kahn, MD, MSc², Philip S Wells, MD, MSc³, David Anderson, MD⁴, Marc Rodger, MD, MSc⁵, Marc Carrier, MD, MSc³, Annmarie A. Bosco, MBBS, BSc (Med)⁶^*, Judy Kovacs, RN⁷^*, Roweena Corpuz, RN⁷^* and Michael J. Kovacs, MD, FRCPC⁸

¹Department of Medicine, Division of Hematology, Western University - London Health Sciences Centre, London, ON, Canada
²Center for Clinical Epidemiology, McGill University, Jewish General Hospital, Montreal, QC, Canada
³Ottawa Hospital Research Institute, Ottawa, ON, Canada
⁴Dalhousie Unv. and Capital District, Halifax, NS, Canada
⁵Department of Hematology, University of Ottawa, Ottawa, ON, Canada
⁶Department of Haematology, Prince of Wales Hospital, Sydney, Australia
⁷London Health Sciences Centre, London, ON, Canada
⁸Department of Medicine, Division of Hematology, London Health Sciences Centre, London, ON, Canada

7:30 PM

894

Xalia, a Non-Interventional Study Comparing Rivaroxaban with Standard Anticoagulation for Initial and Long-Term Therapy in Deep Vein Thrombosis

Alexander G G Turpie, MD¹^*, Lorenzo G Mantovani²^*, Sylvia Haas³^*, Reinhold Kreutz⁴^*, Danja Monje⁵^*, Jonas Schneider⁶^*, Martin van Eickels⁶^*, Martin Gebel⁷^* and Walter Ageno⁸^*

¹Department of Medicine, Hamilton Health Sciences, Hamilton, ON, Canada
²CESP-Center for Public Health Research, University of Milan Bicocca, Monza, Italy
³Vascular Centre, Munich, Germany
⁴Institute of Clinical Pharmacology and Toxicology, Charité Universitätsmedizin, Berlin, Germany
⁵Bayer Vital GmbH, Leverkusen, Germany
⁶Bayer Pharma AG, Berlin, Germany
⁷Bayer Pharma AG, Wuppertal, Germany
⁸Department of Clinical and Experimental Medicine, University of Insubria, Varese, Italy

See more of: Antithrombotic Therapy
See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

332.O2.6 332. Antithrombotic Therapy II